Menu
ÚHKT

Ing. Ota Fuchs, CSc.

odborný pracovník v laboratorních metodách

Tel: +420 221 977 313, +420 221 977 512
Email: Ota.Fuchs@uhkt.cz

Pracoviště:

Impaktované publikace

[1]

Kramarzova, K.; Stuchly, J.; Willasch, A.; Gruhn, B.; Schwarz, J.; Cermak, J.; Machova-Polakova, K.; Fuchs, O.; Stary, J.; Trka, J.; Boublikova, L.

Real-time PCR quantification of major Wilms' tumor gene 1 (WT1) isoforms in acute myeloid leukemia, their characteristic expression patterns and possible functional consequences

[rok vydání 2012, impact factor 10.164 ]

[2]

Pribyl, M.; Hubackova, S.; Moudra, A.; Vancurova, M.; Polackova, H.; Tomas Stopka, T.; Jonasova, A.; Bokorova, R.; Fuchs, O.; et al.

Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes

[rok vydání 2020, impact factor 6.574 ]

[3]

Cmejlova, J.; Hildinger, M.; Cmejla, R.; Fuchs, O.; Zakova, D.; Baum, C.; Jelinek, J.

Impact of splice-site mutations of the human MDR1 cDNA on its stability and expression following retroviral gene transfer

[rok vydání 2006, impact factor 5.293]

[4]

Hájková, H.; Fritz, M.H-Y.; Haškovec, C.; Schwarz, J.; Šálek, C.; Marková, J.; Krejčík, Z.; Dostálová Merkerová, M.; Kostečka, A.; Vostrý, M.; Fuchs, O.; Michalová, K.; Cetkovský, P.; Beneš, V.

CBFB - MYH11 hypomethylation signature and PBX3 differential methylation revealed by targeted bisulfite sequencing in patients with acute myeloid leukemia

[rok vydání 2014, impact factor 4.812 ]

[5]

Brodská, B.; Otevřelová, P.; Šálek, C.; Fuchs, O.; Gašová, Z.; Kuželová, K.

High PD-L1 expression predicts for worse outcome of leukemia patients with concomitant NPM1 and FLT3 mutations

[rok vydání 2019, impact factor 4.556 ]

[6]

Stopka, T.; Zakova, D.; Fuchs, O.; Kubrova, O.; Blafkova, J.; Jelinek, J.; Necas, E.; Zivny, J.

Chromatin remodeling gene SMARCA5 is dysregulated in primitive hematopoietic cells of acute leukemia

[rok vydání 2006, impact factor 3.736]

[7]

Kuželová, K.; Brodská, B.; Fuchs, O.; Dobrovolná, M.; Soukup, P.; Cetkovský, P.

Altered HLA class I profile associated with type A/D nucleophosmin mutation points to possible anti-nucleophosmin immune response in acute myeloid leukemia

[rok vydání 2015, impact factor 3.057 ]

[8]

Hradilek, A.; Fuchs, O.; Neuwirt, J.

Inhibition of heme synthesis decreases transferrin receptor expression in mouse erythroleukemia cells

[rok vydání 2006, impact factor 3.020]

[9]

Fuchs, O.; Kostecka, A.; Provaznikova, D.; Krasna, B.; Brezinova, J.; Filkukova, J.; Kotlin, R.; Kouba, M.; Kobylka, P.; Neuwirtova, R.; Jonasova, A.; Caniga, M.; Schwarz, J.; Markova, J.; Maaloufova, J.; Sponerova, D.; Novakova, L.; Cermak, J.

Nature of frequent deletions in CEBPA

[rok vydání 2009, impact factor 2.901]

[10]

Lemež, P.; Gáliková, J.; Michalová, K.; Fuchs, O.; MacWhannell, A.; Zemanová, Z.; Březinová, J.; Černá, M.; Stejskal, J.

De novo acute myeloid leukemia involving only granulocyte-macrophage line in octogenarians leucocytes over 15 × 10⁹/L exhibit a favorable response to standard-dose induction chemotherapy

[rok vydání 2018, impact factor 2.850 ]

[11]

Kuželová, K.; Brodská, B.; Schetelig, J.; Röllig, C.; Ráčil, Z.; Stickel Walz, J.; Helbig, G.; Fuchs, O.; Vraná, M.; Pecherková, P.; Šálek, C.; Mayer, J.

Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin

[rok vydání 2018, impact factor 2.776 ]

[12]

Hájková, H.; Marková, J.; Haškovec, C.; Šárová, I.; Fuchs, O.; Kostečka, A.; Cetkovský, P.; Michalová, K.; Schwarz, J.

Decreased DNA methylation in acute myeloid leukemia patients with DNMT3A mutations and prognostic implications of DNA methylation

[rok vydání 2012, impact factor 2.764 ]

[13]

Fuchs, O.; Provaznikova, D.; Kocova, M.; Kostecka, A.; Cvekova, P.; Neuwirtova, R.; Kobylka, P.; Cermak, J.; Brezinova, J.; Schwarz, J.; Markova, J.; Salaj, P.; Klamova, H.; Maaloufova, J.; Lemez, P.; Novakova, L.; Benesova, K.

CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin´s lymphoma

[rok vydání 2008, impact factor 2.749]

[14]

Fuchs, O.

Proteomic analysis of serum for identification of potential biomarkers predicting response of patients with refractory multiple myeloma to bortezomib-based therapy

[rok vydání 2017, impact factor 2.658 ]

[15]

Grebeňová, D.; Kuželová, K.; Fuchs, O.; Halada, P.; Havlíček, V.; Marinov, I.; Hrkal, Z.

Interferon-alpha suppresses proliferation of chronic myelogenous leukemia cells K562 by extending cell cycle S-phase without inducing apoptosis

[rok vydání 2006, impact factor 2.549]

[16]

Jonasova, A.; Bokorova, R.; Polak, J.; Vostry, M.; Kostecka, A.; Hajkova, H.; Neuwirtova, R.; Siskova, M.; Sponerova, D.; Cermak, J.; Mikulenkova, D.; Cervinek, L.; Brezinova, J.; Michalova, K.; Fuchs, O.

High level of full length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide

[rok vydání 2014, impact factor 2.544 ]

[17]

Neuwirtova, R.; Fuchs, O.; Holicka, M.; Vostry, M.; Kostecka, A.; Hajkova, H.; Jonasova, A.; Cermak, J.; Cmejla, R.; Pospisilova, D.; Belickova, M.; Siskova, M.; Hochova, I.; Vondrakova, J.; Sponerova, D.; Kadlckova, E.; Novakova, L.; Brezinova, J.; Michalova, K.

Transcription factors Fli1 and EKLF in the differentiation of megakaryocytic and erythroid progenitor in 5q- syndrome and in Diamond-Blackfan anemia

[rok vydání 2012, impact factor 2.396 ]

[18]

Grebeňová, D.; Kuželová, K.; Smetana, K.; Pluskalová, M.; Cajthamlová, H.; Marinov, I.; Fuchs, O.; Souček, J.; Jarolím, P.; Hrkal, Z.

Mitochondrial and endoplasmic reticulum stress-induced apoptotic pathways are activated by 5-aminolevulinic acid-based photodynamic therapy in HL60 leukemia cells

[rok vydání 2006, impact factor 2.275]

[19]

Jonasova, A.; Neuwirtova, R.; Polackova, H.; Siskova, M.; Stopka, T.; Cmunt, E.; Belickova, M.; Moudra, A.; Minarik, L.; Fuchs, O.; Michalova, K.; Zemanova, Z.

Lenalidomide treatment in lower risk myelodysplastic syndromes: the experience of a Czech hematology center. (Positive effect of erythropoietin ± prednisone addition to lenalidomide in refractory or relapsed patients)

[rok vydání 2018, impact factor 2.066 ]

[20]

Fuchs, O.; Simakova, O.; Klener, P.; Cmejlova, J.; Zivny, J.; Zavadil, J.; Stopka, T.

Inhibition of Smad5 in human hematopoietic progenitors blocks erythroid differentiation induced by BMP4

[rok vydání 2006, impact factor 1.772]

Neimpaktované publikace

[1]

Fuchs, O.; Bokorova, R.

Targeted protein degradation using proteolysis targeting chimeras (PROTACs) in hematologic malignancies

[rok vydání 2020]